109 results on '"Kostopoulou, M"'
Search Results
2. Lupus Nephritis: Improving Treatment Options
- Author
-
Kostopoulou, M. Pitsigavdaki, S. Bertsias, G. and Kostopoulou, M. Pitsigavdaki, S. Bertsias, G.
- Abstract
Despite improvements in patient and renal death rates following the introduction of potent immunosuppressive drugs in earlier decades, a sizeable fraction of patients with lupus nephritis is burdened with suboptimal or delayed responses, relapses, chronic use of glucocorticoids and accrual of renal (chronic renal insufficiency) and extra-renal organ damage. The recently approved combinatory treatments comprising belimumab or voclosporin added to conventional agents, especially mycophenolate, hold promise for further improving disease outcomes and enabling a faster steroid tapering, thus being relevant to the treat-to-target context. However, it remains uncertain whether these dual regimens should become the first-line choice for all patients or instead be prioritized to certain subgroups. In the present article, we summarize the existing lupus nephritis management recommendations, followed by a critical appraisal of the randomized trials of belimumab and voclosporin, as well as the available data on obinutuzumab and other novel compounds under development. We conclude that pending the identification of accurate clinical, histological, or translational predictors for guiding personalized decisions, it is of utmost importance that lupus nephritis patients are monitored closely with appropriate treatment adjustments aiming at a prompt, deep response to ensure long-term preservation of kidney function. © 2022, The Author(s), under exclusive licence to Springer Nature Switzerland AG.
- Published
- 2022
3. Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: Implications for the management of early disease
- Author
-
Nikolopoulos, D.S. Nikolopoulos, D.S. Kostopoulou, M. Kostopoulou, M. Pieta, A. Flouda, S. Chavatza, K. Banos, A. Boletis, J. Katsimbri, P. Boumpas, D.T. Boumpas, D.T. Fanouriakis, A. Fanouriakis, A. and Nikolopoulos, D.S. Nikolopoulos, D.S. Kostopoulou, M. Kostopoulou, M. Pieta, A. Flouda, S. Chavatza, K. Banos, A. Boletis, J. Katsimbri, P. Boumpas, D.T. Boumpas, D.T. Fanouriakis, A. Fanouriakis, A.
- Abstract
Objective Changes in the care of patients with SLE dictate a re-evaluation of its natural history and risk factors for disease deterioration and damage accrual. We sought to decipher factors predictive of a deterioration in phenotype ('transition') in patients initially presenting with non-severe disease. Methods Patients from the 'Attikon' cohort with disease duration ≥1 year were included. Disease at diagnosis was categorised as mild, moderate or severe, based on the British Isles Lupus Assessment Group manifestations and physician judgement. 'Transition' in severity was defined as an increase in category of severity at any time from diagnosis to last follow-up. Multivariable logistic regression was performed to identify baseline factors associated with this transition. Results 462 patients were followed for a median (IQR) of 36 (120) months. At diagnosis, more than half (56.5%) had a mild phenotype. During disease course, transition to more severe forms was seen in 44.2%, resulting in comparable distribution among severity patterns at last follow-up (mild 28.4%, moderate 33.1%, severe 38.5%). Neuropsychiatric involvement at onset (OR 6.33, 95% CI 1.22 to 32.67), male sex (OR 4.53, 95% CI 1.23 to 16.60) and longer disease duration (OR 1.09 per 1 year, 95% CI 1.04 to 1.14) were independently associated with transition from mild or moderate to severe disease. Patients with disease duration ≥3 years who progressed to more severe disease had more than 20-fold increased risk to accrue irreversible damage. Conclusion Almost half of patients with initially non-severe disease progress to more severe forms of SLE, especially men and patients with positive anti-double-stranded DNA or neuropsychiatric involvement at onset. These data may have implications for the management of milder forms of lupus. © 2020 Lupus Science and Medicine. All right reserved.
- Published
- 2020
4. Thought-shape fusion in bulimia nervosa: An experimental investigation
- Author
-
Kostopoulou, M., Varsou, E., and Stalikas, A.
- Published
- 2011
- Full Text
- View/download PDF
5. EULAR RECOMMENDATION-BASED QUALITY INDICATORS (QIS) FOR SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): ELABORATION, FINAL SET, PERFORMANCE AND INITIAL VALIDATION
- Author
-
Chavatza, K. Kostopoulou, M. Nikolopoulos, D. Gioti, O. and Togia, K. Flouda, S. Kapsala, N. Kosmetatou, M. and Moysidou, G. S. Grivas, A. Pieta, A. Ntourou, A. and Rapsomaniki, P. Gerogianni, T. Tseronis, D. Aggelakos, M. and Karageorgas, T. Katsimpri, P. Andreoli, L. Aringer, M. and Boletis, N. Doria, A. Houssiau, F. Jayne, D. Mosca, M. Svenungsson, E. Tincani, A. Bertsias, G. Fanouriakis, A. Boumpas, D.
- Published
- 2021
6. Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: Development and initial validation in a cohort of 220 patients
- Author
-
Chavatza, K. Kostopoulou, M. Nikolopoulos, D. Gioti, O. Togia, K. Andreoli, L. Aringer, M. Boletis, J. Doria, A. Houssiau, F.A. Jayne, D. Mosca, M. Svenungsson, E. Tincani, A. Bertsias, G. Fanouriakis, A. Boumpas, D.T.
- Abstract
Quality of care is receiving increased attention in systemic lupus erythematosus (SLE). We developed quality indicators (QIs) for SLE based on the 2019 update of European League Against Rheumatism recommendations. A total of 44 candidate QIs corresponding to diagnosis, monitoring and treatment, were independently rated for validity and feasibility by 12 experts and analysed by a modified Research and Development Corporation/University of California Los Angeles model. Adherence to the final set of QIs and correlation with disease outcomes (flares, hospitalisations and organ damage) was tested in a cohort of 220 SLE patients with a median monitoring of 2 years (IQR 2–4). The panel selected a total of 18 QIs as valid and feasible. On average, SLE patients received 54% (95% CI 52.3% to 56.2%) of recommended care, with adherence ranging from 44.7% (95% CI 40.8% to 48.6%) for diagnosis-related QIs to 84.3% (95% CI 80.6% to 87.5%) for treatment-related QIs. Sustained remission or low disease activity were achieved in 26.8% (95% CI 21.1% to 33.2%). Tapering of prednisone dose to less than 7.5 mg/day was achieved in 93.6% (95% CI 88.2% to 97.0%) while 73.5% (95% CI 66.6% to 79.6%) received the recommended hydroxychloroquine dose. Higher adherence to monitoring-related QIs was associated with reduced risk for a composite adverse outcome (flare, hospitalisation or damage accrual) during the last year of observation (OR 0.97 per 1% adherence rate, 95% CI 0.96 to 0.99). We developed QIs for assessing and improving the care of SLE patients. Initial real-life data suggest face validity, but a variable degree of adherence and a need for further improvement. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
- Published
- 2021
7. POS0764 EULAR RECOMMENDATION-BASED QUALITY INDICATORS (QIS) FOR SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): ELABORATION, FINAL SET, PERFORMANCE AND INITIAL VALIDATION
- Author
-
Chavatza, K., primary, Kostopoulou, M., additional, Nikolopoulos, D., additional, Gioti, O., additional, Togia, K., additional, Flouda, S., additional, Kapsala, N., additional, Kosmetatou, M., additional, Moysidou, G. S., additional, Grivas, A., additional, Pieta, A., additional, Ntourou, A., additional, Rapsomaniki, P., additional, Gerogianni, T., additional, Tseronis, D., additional, Aggelakos, M., additional, Karageorgas, T., additional, Katsimpri, P., additional, Andreoli, L., additional, Aringer, M., additional, Boletis, J. N., additional, Doria, A., additional, Houssiau, F., additional, Jayne, D., additional, Mosca, M., additional, Svenungsson, E., additional, Tincani, A., additional, Bertsias, G., additional, Fanouriakis, A., additional, and Boumpas, D., additional
- Published
- 2021
- Full Text
- View/download PDF
8. OP0163 2019 UPDATE OF THE JOINT EUROPEAN LEAGUE AGAINST RHEUMATISM AND EUROPEAN RENAL ASSOCIATION–EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION (EULAR/ERA-EDTA) RECOMMENDATIONS FOR THE MANAGEMENT OF LUPUS NEPHRITIS
- Author
-
Fanouriakis, A., primary, Kostopoulou, M., additional, Cheema, K., additional, Anders, H. J., additional, Aringer, M., additional, Bajema, I., additional, Boletis, J. N., additional, Frangou, E., additional, Houssiau, F., additional, Hollis, J., additional, Karras, A., additional, Marchiori, F., additional, Marks, S., additional, Moroni, G., additional, Mosca, M., additional, Parodis, I., additional, Praga, M., additional, Schneider, M., additional, Smolen, J. S., additional, Tesar, V., additional, Trachana, M., additional, Vollenhoven, R. V., additional, Voskuyl, A., additional, Teng, Y. K. O., additional, Van Leeuw, B., additional, Bertsias, G., additional, Jayne, D., additional, and Boumpas, D., additional
- Published
- 2020
- Full Text
- View/download PDF
9. SAT0173 A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2019 UPDATE OF THE JOINT EUROPEAN LEAGUE AGAINST RHEUMATISM AND EUROPEAN RENAL ASSOCIATION–EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION (EULAR/ERA-EDTA) RECOMMENDATIONS FOR THE MANAGEMENT OF LUPUS NEPHRITIS
- Author
-
Fanouriakis, A., primary, Kostopoulou, M., additional, Cheema, K., additional, Bertsias, G., additional, Jayne, D., additional, and Boumpas, D., additional
- Published
- 2020
- Full Text
- View/download PDF
10. Cardiovascular disease in systemic lupus erythematosus: Recent data on epidemiology, risk factors and prevention
- Author
-
Kostopoulou, M. Nikolopoulos, D. Parodis, I. Bertsias, G.
- Abstract
Systemic Lupus Erythematosus (SLE) is associated with increased risk for accelerated atherosclerosis and cardiovascular (CV) events including coronary heart disease, cerebrovascular and peripheral artery disease. CV events occur both early and late during the disease course, with younger patients being at much higher risk than age-matched counterparts. The risk cannot be fully accounted for by the increased prevalence of traditional atherosclerotic factors and may be due to pathophysiologic intermediates such as type I interferons and other inflammatory cytokines, oxidative stress, activated granulocytes and production of extracellular chromatin traps, antiphospholipid and other autoantibodies causing dysfunction of lipoproteins, altogether resulting in endothelial injury and pro-atherogenic dyslipidaemia. These mechanisms may be further aggravated by chronic intake of prednisone (even at doses
- Published
- 2020
11. 2019 Update of the Joint European League against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis
- Author
-
Fanouriakis, A. Kostopoulou, M. Cheema, K. Anders, H. J. and Aringer, M. Bajema, I. Boletis, J. N. Frangou, E. and Houssiau, F. Hollis, J. Karras, A. Marchiori, F. Marks, S. Moroni, G. Mosca, M. Parodis, I. Praga, M. and Schneider, M. Smolen, J. S. Tesar, V. Trachana, M. and Vollenhoven, R. V. Voskuyl, A. Teng, Y. K. O. Van Leeuw, B. and Bertsias, G. Jayne, D. Boumpas, D.
- Abstract
Objective To update the 2012 EULAR/ERA-EDTA recommendations for the management of lupus nephritis (LN). Methods Following the EULAR standardised operating procedures, a systematic literature review was performed. Members of a multidisciplinary Task Force voted independently on their level of agreeement with the formed statements. Results The changes include recommendations for treatment targets, use of glucocorticoids and calcineurin inhibitors (CNIs) and management of end-stage kidney disease (ESKD). The target of therapy is complete response (proteinuria 1 g/24 hours despite renin-Angiotensin-Aldosterone blockade, MMF in combination with glucocorticoids is preferred. Assessment for kidney and extra-renal disease activity, and management of comorbidities is lifelong with repeat kidney biopsy in cases of incomplete response or nephritic flares. In ESKD, transplantation is the preferred kidney replacement option with immunosuppression guided by transplant protocols and/or extra-renal manifestations. Treatment of LN in children follows the same principles as adult disease. Conclusions We have updated the EULAR recommendations for the management of LN to facilitate homogenization of patient care. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
- Published
- 2020
12. A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2019 UPDATE OF THE JOINT EUROPEAN LEAGUE AGAINST RHEUMATISM AND EUROPEAN RENAL ASSOCIATION-EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION (EULAR/ERA-EDTA) RECOMMENDATIONS FOR THE MANAGEMENT OF LUPUS NEPHRITIS
- Author
-
Fanouriakis, A. Kostopoulou, M. Cheema, K. Bertsias, G. and Jayne, D. Boumpas, D.
- Published
- 2020
13. An Update on the Diagnosis and Management of Lupus Nephritis
- Author
-
Kostopoulou, M. Adamichou, C. Bertsias, G.
- Abstract
Purpose of Review: Update on the diagnosis, treatment, and monitoring of lupus nephritis. Recent Findings: The recent criteria enable the earlier classification of lupus nephritis based on kidney biopsy and compatible serology. Treatment of active nephritis includes low-dose intravenous cyclophosphamide or mycophenolate, followed by maintenance immunosuppression. Recent trials have suggested superiority of regimens combining mycophenolate with either calcineurin inhibitor or belimumab, although their long-term benefit/risk ratio has not been determined. Encouraging results with novel anti-CD20 antibodies confirm the effectiveness of B cell depletion. Achievement of low-grade proteinuria (< 700–800 mg/24 h) at 12-month post-induction is linked to favorable long-term outcomes and could be considered in a treat-to-target strategy. Also, repeat kidney biopsy can guide the duration of maintenance immunosuppression. Lupus nephritis has increased cardiovascular disease burden necessitating risk-reduction strategies. Summary: An expanding spectrum of therapies coupled with ongoing basic/translational research can lead to individualized medical care and improved outcomes in lupus nephritis. © 2020, Springer Science+Business Media, LLC, part of Springer Nature.
- Published
- 2020
14. Management of lupus nephritis: A systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations
- Author
-
Kostopoulou, M. Fanouriakis, A. Cheema, K. Boletis, J. Bertsias, G. Jayne, D. Boumpas, D.T.
- Abstract
Objectives To analyse the current evidence for the management of lupus nephritis (LN) informing the 2019 update of the EULAR/European Renal Association-European Dialysis and Transplant Association recommendations. Methods According to the EULAR standardised operating procedures, a PubMed systematic literature review was performed, from January 1, 2012 to December 31, 2018. Since this was an update of the 2012 recommendations, the final level of evidence (LoE) and grading of recommendations considered the total body of evidence, including literature prior to 2012. Results We identified 387 relevant articles. High-quality randomised evidence supports the use of immunosuppressive treatment for class III and class IV LN (LoE 1a), and moderate-level evidence supports the use of immunosuppressive treatment for pure class V LN with nephrotic-range proteinuria (LoE 2b). Treatment should aim for at least 25% reduction in proteinuria at 3 months, 50% at 6 months and complete renal response (
- Published
- 2020
15. Evolving phenotype of systemic lupus erythematosus in Caucasians: low incidence of lupus nephritis, high burden of neuropsychiatric disease and increased rates of late-onset lupus in the ‘Attikon’ cohort
- Author
-
Nikolopoulos, D. Kostopoulou, M. Pieta, A. Karageorgas, T. Tseronis, D. Chavatza, K. Flouda, S. Rapsomaniki, P. Banos, A. Kremasmenou, E. Tzavara, V. Katsimbri, P. Fanouriakis, A. Boumpas, D.T.
- Subjects
skin and connective tissue diseases - Abstract
Objective: This study aimed to analyse the phenotype of systemic lupus erythematosus (SLE) at first presentation and during follow-up in a newly established SLE cohort based at ‘Attikon’ University Hospital. The hospital combines primary, secondary and tertiary care for the region of Western Attica, Greece. Methods: This study comprised a mixed prevalent and incident cohort of 555 Caucasian patients diagnosed with SLE according to American College of Rheumatology 1997 criteria and/or the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) 2012 criteria. Demographic and clinical characteristics, patterns of severity, treatments and SLICC damage index were recorded for each patient at the time of diagnosis and at last evaluation. Results: The mean age at lupus diagnosis was 38.3 years (standard deviation = 15.6 years), with a median disease duration at last follow-up of two years (interquartile range 1-11). At initial presentation, the most common ‘classification’ manifestations were arthritis (73.3%), acute cutaneous lupus (65%) and unexplained fever (25%), while among symptoms not included in any criteria set, Raynaud’s phenomenon (33%) was the most common. Kidney and neuropsychiatric involvement as presenting manifestations were present in 10.3% and 11.5% cases, respectively. Irreversible damage accrual was present in 17.8% within six months of disease diagnosis, attributed mainly to thrombotic and neuropsychiatric disease. At last evaluation, 202 (36.4%) patients had developed severe disease, of whom more than half were treated with pulse cyclophosphamide. Conclusion: In this cohort of Caucasian patients, lupus nephritis is not as common as in older cohorts, while neuropsychiatric disease is emerging as a major frontier in lupus prevention and care. These data may help to document changes in the natural history and treatment of SLE over time and may have implications for its early recognition and management. © The Author(s) 2020.
- Published
- 2020
16. 2019 Update of the Joint European League against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis
- Author
-
Fanouriakis, A. Kostopoulou, M. Cheema, K. Anders, H.-J. Aringer, M. Bajema, I. Boletis, J. Frangou, E. Houssiau, F.A. Hollis, J. Karras, A. Marchiori, F. Marks, S.D. Moroni, G. Mosca, M. Parodis, I. Praga, M. Schneider, M. Smolen, J.S. Tesar, V. Trachana, M. Van Vollenhoven, R.F. Voskuyl, A.E. Teng, Y.K.O. Van Leew, B. Bertsias, G. Jayne, D. Boumpas, D.T. and Fanouriakis, A. Kostopoulou, M. Cheema, K. Anders, H.-J. Aringer, M. Bajema, I. Boletis, J. Frangou, E. Houssiau, F.A. Hollis, J. Karras, A. Marchiori, F. Marks, S.D. Moroni, G. Mosca, M. Parodis, I. Praga, M. Schneider, M. Smolen, J.S. Tesar, V. Trachana, M. Van Vollenhoven, R.F. Voskuyl, A.E. Teng, Y.K.O. Van Leew, B. Bertsias, G. Jayne, D. Boumpas, D.T.
- Abstract
Objective To update the 2012 EULAR/ERA-EDTA recommendations for the management of lupus nephritis (LN). Methods Following the EULAR standardised operating procedures, a systematic literature review was performed. Members of a multidisciplinary Task Force voted independently on their level of agreeement with the formed statements. Results The changes include recommendations for treatment targets, use of glucocorticoids and calcineurin inhibitors (CNIs) and management of end-stage kidney disease (ESKD). The target of therapy is complete response (proteinuria <0.5-0.7 g/24 hours with (near-)normal glomerular filtration rate) by 12 months, but this can be extended in patients with baseline nephrotic-range proteinuria. Hydroxychloroquine is recommended with regular ophthalmological monitoring. In active proliferative LN, initial (induction) treatment with mycophenolate mofetil (MMF 2-3 g/day or mycophenolic acid (MPA) at equivalent dose) or low-dose intravenous cyclophosphamide (CY; 500 mg × 6 biweekly doses), both combined with glucocorticoids (pulses of intravenous methylprednisolone, then oral prednisone 0.3-0.5 mg/kg/day) is recommended. MMF/CNI (especially tacrolimus) combination and high-dose CY are alternatives, for patients with nephrotic-range proteinuria and adverse prognostic factors. Subsequent long-Term maintenance treatment with MMF or azathioprine should follow, with no or low-dose (<7.5 mg/day) glucocorticoids. The choice of agent depends on the initial regimen and plans for pregnancy. In non-responding disease, switch of induction regimens or rituximab are recommended. In pure membranous LN with nephrotic-range proteinuria or proteinuria >1 g/24 hours despite renin-Angiotensin-Aldosterone blockade, MMF in combination with glucocorticoids is preferred. Assessment for kidney and extra-renal disease activity, and management of comorbidities is lifelong with repeat kidney biopsy in cases of incomplete response or nephritic flares. In ESKD, transplan
- Published
- 2020
17. A study into dentistsʼ knowledge of the treatment of traumatic injuries to young permanent incisors
- Author
-
KOSTOPOULOU, M. N. and DUGGAL, M. S.
- Published
- 2005
18. Prevention and treatment of childhood and adolescent obesity: a systematic review of meta-analyses
- Author
-
Psaltopoulou, T. Tzanninis, S. Ntanasis-Stathopoulos, I. Panotopoulos, G. Kostopoulou, M. Tzanninis, I.-G. Tsagianni, A. Sergentanis, T.N.
- Abstract
Background: The goal of this systematic review is to synthesize the published meta-analyses assessing the role of nutritional, behavioral and physical activity factors/interventions on the prevention or treatment of pediatric and adolescent obesity. Methods: An online search was conducted in PubMed (end-of-search: September 30, 2015); English-language meta-analyses pooling observational and/or interventional studies examining weight-related indices on children and adolescents were included. Results: Sixty-six meta-analyses corresponding to more than 900,000 children and adolescents were retrieved. The majority of meta-analyses included interventional studies most of which referred to mixed or combined interventions, including components such as diet, physical activity and sedentary behavior reduction. Discrepancies between meta-analyses on observational and interventional studies were noted. Combined interventions including physical activity and nutritional modifications seemed to represent the most effective means for tackling childhood obesity. Conclusions: Synthesis of interventional or observational evidence may yield discrepant results. The combination of enhanced physical activity and improved nutrition emerged as a promising intervention in the fight against childhood/adolescent obesity. However, further research is needed about the most effective multidimensional prevention strategy. © 2019, Children's Hospital, Zhejiang University School of Medicine.
- Published
- 2019
19. Hereditary systemic amyloidosis caused by K19T apolipoprotein C-II variant
- Author
-
Liapis, K. Panagopoulou, P. Charitaki, E. Rowczenio, D. Gilbertson, J. Papathoma, A. Kostopoulou, M. Dimopoulos, M.A. Gillmore, J.D. Kastritis, E.
- Published
- 2019
20. 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus
- Author
-
Fanouriakis, A. Kostopoulou, M. Alunno, A. Aringer, M. Bajema, I. Boletis, J.N. Cervera, R. Doria, A. Gordon, C. Govoni, M. Houssiau, F. Jayne, D. Kouloumas, M. Kuhn, A. Larsen, J.L. Lerstrøm, K. Moroni, G. Mosca, M. Schneider, M. Smolen, J.S. Svenungsson, E. Tesar, V. Tincani, A. Troldborg, A. Van Vollenhoven, R. Wenzel, J. Bertsias, G. Boumpas, D.T.
- Subjects
skin and connective tissue diseases - Abstract
Our objective was to update the EULAR recommendations for the management of systemic lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic literature review (01/2007-12/2017), followed by modified Delphi method, to form questions, elicit expert opinions and reach consensus. Treatment in SLE aims at remission or low disease activity and prevention of flares. Hydroxychloroquine is recommended in all patients with lupus, at a dose not exceeding 5 mg/kg real body weight. During chronic maintenance treatment, glucocorticoids (GC) should be minimised to less than 7.5 mg/day (prednisone equivalent) and, when possible, withdrawn. Appropriate initiation of immunomodulatory agents (methotrexate, azathioprine, mycophenolate) can expedite the tapering/discontinuation of GC. In persistently active or flaring extrarenal disease, add-on belimumab should be considered; rituximab (RTX) may be considered in organ-threatening, refractory disease. Updated specific recommendations are also provided for cutaneous, neuropsychiatric, haematological and renal disease. Patients with SLE should be assessed for their antiphospholipid antibody status, infectious and cardiovascular diseases risk profile and preventative strategies be tailored accordingly. The updated recommendations provide physicians and patients with updated consensus guidance on the management of SLE, combining evidence-base and expert-opinion. © 2019 Author(s).
- Published
- 2019
21. Evolving phenotype of systemic lupus erythematosus in Caucasians: low incidence of lupus nephritis, high burden of neuropsychiatric disease and increased rates of late-onset lupus in the ‘Attikon’ cohort
- Author
-
Nikolopoulos, D, primary, Kostopoulou, M, additional, Pieta, A, additional, Karageorgas, T, additional, Tseronis, D, additional, Chavatza, K, additional, Flouda, S, additional, Rapsomaniki, P, additional, Banos, A, additional, Kremasmenou, E, additional, Tzavara, V, additional, Katsimbri, P, additional, Fanouriakis, A, additional, and Boumpas, D T, additional
- Published
- 2020
- Full Text
- View/download PDF
22. Norganic and organic contamination in sediment from Izmir Bay (Turkey) and Mytilene harbor (Greece)
- Author
-
Kostopoulou, M., mco guida, Nikolaou, A., Oral, R., Trifuoggi, M., Borriello, I., Vagi, M., D Ambra, L., Meric-Pagano, S., Pagano, G., Kostopoulou, M., Guida, Marco, Nikolaou, A., Oral, R., Trifuoggi, Marco, Borriello, I., Vagi, M., D'Ambra, Luigi, Meric Pagano, S., and Pagano, G.
- Subjects
Harbor pollution, Inorganics, Marine sediment, Polycyclic aromatic hydrocarbons - Abstract
Marine sediment contamination was evaluated in a set of sediment specimens collected from Izmir Bay (Turkey) and from Mytilene Harbor (Greece) in the Aegean Sea. Eight sediment specimens from Izmir (#IZ to #IZ8) and seven sediment specimens from Mytilene (#MYT1 to #MYT7) were analyzed for their content in different classes of contaminants, i.e. inorganics, organic carbon (OC), and seven polycyclic aromatic hydrocarbons (PAHs). Significantly higher levels of inorganic contaminants were detected in Izmir vs. Mytilene sediment, and the highest inorganic contamination was detected in the innermost sampling sites in Izmir Bay, namely sites #IZ1 to #IZ4. This was the case for Al, As, Cr, Cu, Fe, Li, Mn, Pb, Ti and Zn. Granulometric analysis, OC and individual PAH congeners failed to show any significant differences between total Mytilene and total Izmir Bay sediment samples. Nevertheless, the sum of PAHs in sites #IZ2 to #IZ4 displayed significantly higher levels both vs. the other Izmir sites and vs. all Mytilene sediment samples. The overall results point to higher pollution status in Izmir Bay, especially in the innermost sampling sites, compared to Mytilene harbor, detected as inorganic contamination and as PAH contamination in some Izmir sampling sites.
- Published
- 2013
23. Marine Sediment Contamination and Toxicity in Izmir Bay and Mytilene Harbor (Aegean Sea)
- Author
-
Oral R, Kostopoulou M, Guida M, Nikolaou Anastasia, Quiniou F, Trifuoggi M, Borriello I, Vagi M, Pagano G., D'AMBRA, Antonello, Oral, R, Kostopoulou, M, Guida, M, Nikolaou, Anastasia, Quiniou, F, Trifuoggi, M, Borriello, I, Vagi, M, D'Ambra, Antonello, and Pagano, G.
- Subjects
sediment toxicity ,pore water ,whole sediment - Abstract
The aim of the present study was to evaluate marine contamination and toxicity in sediment and pore water from the areas of Izmir Bay (Turkey) and Mytilene Harbor (Greece). The evaluation was performed in terms of selected toxic metals, polycyclic aromatic compounds (PAH) and toxicity to sea urchin (Paracentrotus lividus) early development and fertilization. Significantly higher levels of metals and total PAH were detected in Izmir vs. Mytilene sediment, and the highest contamination was detected in Izmir Bay innermost sites. Bioassays were carried out in P. lividus embryos and sperm, by evaluating developmental defects and changes in fertilization success by exposing sea urchin embryos or sperm to sediment/seawater suspensions. Whole sediment (WS) showed a higher toxicity of Izmir vs. Mytilene samples both in terms of developmental defects and of spermiotoxicity. Pore water (PW) and solid phase (SP) were separated by WS centrifugation and tested on embryos or sperm. The induction of developmental defects showed a significantly higher toxicity of WS compared to SP and, even more so, to PW. A significant decrease in fertilization success was observed following sperm suspension in SP from both Izmir and Mytilene sediment samples, whereas PW-exposed sperm failed to display any decrease of fertilization success vs. controls. The use of WS bioassays is suggested as a default procedure in sediment toxicity testing, especially in a topographic characterization of polluted sediments.
- Published
- 2012
24. Ecosystem Services and spatial planning in sensitive and vulnerable coastal areas: a case study in the Aegean Sea
- Author
-
Karydis, M., Kitsiou, D., Kostopoulou, M., and Pavlogeorgatos, G.
- Published
- 2015
- Full Text
- View/download PDF
25. Thought-shape fusion in anorexia and bulimia nervosa: A comparative experimental study
- Author
-
Kostopoulou, M. Varsou, E. Stalikas, A.
- Abstract
'Thought-shape fusion' (TSF) is a cognitive distortion specific in patients with eating disorders and occurs when the thought about eating a forbidden food increases a person's estimate of her weight/shape, elicits a perception of moral wrongdoing and makes her feel fat. This study aimed to experimentally induce, study and compare TSF between patients with bulimia nervosa (BN) and patients with anorexia nervosa (AN). 31 patients diagnosed with a current eating disorder, of which 20 met DSM-IV-TR criteria for BN and 11 for AN, participated in a mixed-model experimental design with the aim of eliciting TSF and investigating the effects of corrective behaviors (checking and mental neutralizing). Verbal analogue scales constituted the main outcome measures. TSF was experimentally induced and expressed in a similar way in both clinical groups, apart from 'feeling fat' which was higher in BN patients. TSF induction triggered heightened levels of anxiety, guilt and urges to engage in corrective behaviors in both groups. Body dissatisfaction only increased in the BN patients. Mental neutralizing and to a lesser extent checking reduced most effects of the experimental procedure, but this effect was larger for BN patients. The nature of TSF seems to have similarities between BN and AN patients; however, the precise connection between TSF and different types of eating disorders remains to be explored in future clinical trials. © 2013 Springer International Publishing Switzerland.
- Published
- 2013
26. Intracellular eukaryotic pathogens in brown macroalgae in the Eastern Mediterranean, including LSU rRNA data for the oomycete Eurychasma dicksonii
- Author
-
Strittmatter, M. Gachon, C.M.M. Müller, D.G. Kleinteich, J. Heesch, S. Tsirigoti, A. Katsaros, C. Kostopoulou, M. Küpper, F.C.
- Abstract
For the Mediterranean Sea, and indeed most of the world's oceans, the biodiversity and biogeography of eukaryotic pathogens infecting marine macroalgae remains poorly known, yet their ecological impact is probably significant. Based on 2 sampling campaigns on the Greek island of Lesvos in 2009 and 1 in northern Greece in 2012, this study provides first records of 3 intracellular eukaryotic pathogens infecting filamentous brown algae at these locations: Eurychasma dicksonii, Anisolpidium sphacellarum, and A. ectocarpii. Field and microscopic observations of the 3 pathogens are complemented by the first E. dicksonii large subunit ribosomal RNA (LSU rRNA) gene sequence analyses of isolates from Lesvos and other parts of the world. The latter highlights the monophyly of E. dicksonii worldwide and confirms the basal position of this pathogen within the oomycete lineage (Peronosporomycotina). The results of this study strongly support the notion that the geographic distribution of the relatively few eukaryotic seaweed pathogens is probably much larger than previously thought and that many of the world's marine bioregions remain seriously undersampled and understudied in this respect. © Inter-Research 2013.
- Published
- 2013
27. Marine sediment contamination and toxicity in Izmir Bay and Mytilene harbor (Aegean Sea) [İzmir körfezi ve midilli limani{dotless}'nda (Ege Denizi) denizel sediment bulaşmasi{dotless} ve toksisitesi]
- Author
-
Oral R., Kostopoulou M., Guida M., Nikolaou A., Quiniou F., Trifuoggi M., Borriello I., Vagi M., D'Ambra A., Pagano G., and Ege Üniversitesi
- Subjects
Aegean sea ,Sediment toxicity ,Whole sediment ,Sea urchins ,Pore water - Abstract
The aim of the present study was to evaluate marine contamination and toxicity in sediment and pore water from the areas of Izmir Bay (Turkey) and Mytilene Harbor (Greece). The evaluation was performed in terms of selected toxic metals, polycyclic aromatic compounds (PAH) and toxicity to sea urchin (Paracentrotus lividus) early development and fertilization. Significantly higher levels of metals and total PAH were detected in Izmir vs. Mytilene sediment, and the highest contamination was detected in Izmir Bay innermost sites. Bioassays were carried out in P. lividus embryos and sperm, by evaluating developmental defects and changes in fertilization success by exposing sea urchin embryos or sperm to sediment/seawater suspensions. Whole sediment (WS) showed a higher toxicity of Izmir vs. Mytilene samples both in terms of developmental defects and of spermiotoxicity. Pore water (PW) and solid phase (SP) were separated by WS centrifugation and tested on embryos or sperm. The induction of developmental defects showed a significantly higher toxicity of WS compared to SP and, even more so, to PW. A significant decrease in fertilization success was observed following sperm suspension in SP from both Izmir and Mytilene sediment samples, whereas PW-exposed sperm failed to display any decrease of fertilization success vs. controls. The use of WS bioassays is suggested as a default procedure in sediment toxicity testing, especially in a topographic characterization of polluted sediments. © Published by Central Fisheries Research Institute (CFRI) Trabzon, Turkey.
- Published
- 2012
28. Thought-shape fusion in bulimia nervosa: An experimental investigation
- Author
-
Kostopoulou, M. Varsou, E. Stalikas, A.
- Abstract
The aim of the present study was to experimentally investigate a cognitive distortion, 'Thought Shape Fusion' (TSF), in patients with bulimia nervosa (BN). TSF has been postulated as a specific distortion in patients with eating disorders and occurs when the thought about eating a forbidden food increases a person's estimate of her weight / shape, elicits a perception of moral wrongdoing and makes her feel fat. Previous psychometric measures of TSF in clinical and control groups, experiments eliciting TSF in a student sample and in patients with anorexia nervosa, all confirm a strong association between TSF and eating disorder psychopathology. Twenty patients diagnosed with BN participated in a within-participants experimental design with the aim of eliciting TSF and investigating further the possible effects of corrective behaviours (checking and mental neutralizing). Verbal analogue scales constituted the main outcome measures. TSF triggered a perception of moral wrongdoing, heightened levels of body dissatisfaction, elevated feelings of anxiety and guilt and prompted urges to engage in checking and mental neutralizing. Corrective behaviours significantly reduced the effects of the experimental procedure. Components of TSF are present in BN and are likely to play a mediating role in the maintenance of the disorder. The precise connection between TSF and BN remains to be explored in future clinical trials. ©2011, Editrice Kurtis.
- Published
- 2011
29. Determination of Polyciclic Aromatic Hydrocarbons in the harbour sediments of Mytilene, Greece
- Author
-
Kostopoulou, M, Mylona, A, Nikolau, A, Lofrano, Giusy, and Meric, S. AND BELGIORNO V.
- Published
- 2007
30. Evaluation of the pollution of the surface waters of Greece from the priority compounds of List II, 76/464/EEC Directive, and other toxic compounds
- Author
-
Lekkas, T. Kolokythas, G. Nikolaou, A. Kostopoulou, M. Kotrikla, A. Gatidou, G. Thomaidis, N.S. Golfinopoulos, S. Makri, C. Babos, D. Vagi, M. Stasinakis, A. Petsas, A. Lekkas, D.F.
- Abstract
The pollution of the surface waters of Greece from the priority compounds of 76/464/EEC Directive was evaluated. The occurrence of 92 toxic compounds, 64 of which belong to priority compounds of List II, candidates for List I, of 76/464/EEC Directive, was studied in surface waters and wastewater through the developed network of 62 sampling stations, which covers the whole Greek territory. The analytical determination was performed by Purge and Trap-Gas chromatography-Mass spectrometry for volatile and semivolatile organic compounds (VOCs), Gas Chromatography-Electron Capture Detection for organochlorine insecticides, Gas Chromatography-Nitrogen Phosphorous Detection for organophosphorous insecticides, High Performance Liquid Chromatography-Photodiode Array Detection for herbicides, and Electrothermal Atomic Absorption Spectrophotometry and Inductively Coupled Plasma-Atomic Emission Spectrometry (ICP-AES) for metals and the toluene extractable organotin compounds. The concentrations of VOCs and insecticides detected in the surface waters of Greece were very low, whereas the concentrations of herbicides and metals ranged generally at moderate levels. VOCs were detected almost exclusively in the rivers and very rarely in the lakes, while the frequency of occurrence of insecticides, herbicides and metals was similar for rivers and lakes. Water quality objectives (WQO) and emission limit values (ELV) have been laid down in national legal framework for a number of compounds detected in the samples, in order to safeguard the quality of surface waters from any future deterioration. © 2004 Elsevier Ltd. All rights reserved.
- Published
- 2004
31. Lab methods / biomarkers
- Author
-
Borras, M., primary, Roig, J., additional, Betriu, A., additional, Vilar, A., additional, Hernandez, M., additional, Martin, M., additional, Fernandez, E. D., additional, Dounousi, E., additional, Kiatou, V., additional, Papagianni, A., additional, Zikou, X., additional, Pappas, K., additional, Pappas, E., additional, Tatsioni, A., additional, Tsakiris, D., additional, Siamopoulos, K. C., additional, Kim, J.-K., additional, Kim, Y., additional, Kim, S. G., additional, Kim, H. J., additional, Ahn, S. Y., additional, Chin, H. J., additional, Oh, K.-H., additional, Ahn, C., additional, Chae, D.-W., additional, Yazici, R., additional, Altintepe, L., additional, Bakdik, S., additional, Guney, I., additional, Arslan, S., additional, Topal, M., additional, Karagoz, A., additional, Stefan, G., additional, Mircescu, G., additional, Capusa, C., additional, Stancu, S., additional, Petrescu, L., additional, Alecu, S., additional, Nedelcu, D., additional, Bennett, A. H. L., additional, Pham, H., additional, Garrity, M., additional, Magdeleyns, E., additional, Vermeer, C., additional, Zhang, M., additional, Ni, Z., additional, Zhu, M., additional, Yan, J., additional, Mou, S., additional, Wang, Q., additional, Qian, J., additional, Saade, A., additional, Karavetian, M., additional, ElZein, H., additional, de Vries, N., additional, de Haseth, D. E., additional, Lay Penne, E., additional, van Dam, B., additional, Bax, W. A., additional, Bots, M. L., additional, Grooteman, M. P. C., additional, van den Dorpel, R. A., additional, Blankenstijn, P. J., additional, Nube, M. J., additional, Wee, P. M., additional, Park, J. H., additional, Jo, Y.-I., additional, Lee, J. H., additional, Cianfrone, P., additional, Comi, N., additional, Lucisano, G., additional, Piraina, V., additional, Talarico, R., additional, Fuiano, G., additional, Toyonaga, M., additional, Fukami, K., additional, Yamagishi, S.-i., additional, Kaida, Y., additional, Nakayama, Y., additional, Ando, R., additional, Obara, N., additional, Ueda, S., additional, Okuda, S., additional, Granatova, J., additional, Havrda, M., additional, Hruskova, Z., additional, Tesar, V., additional, Viklicky, O., additional, Rysava, R., additional, Rychlik, I., additional, Kratka, K., additional, Honsova, E., additional, Vernerova, Z., additional, Maluskova, J., additional, Vranova, J., additional, Bolkova, M., additional, Borecka, K., additional, Benakova, H., additional, Zima, T., additional, Lu, K.-C., additional, Yang, H.-Y., additional, Su, S.-L., additional, Cao, Y.-H., additional, Lv, L.-L., additional, Liu, B.-C., additional, Zeng, R., additional, Gao, X.-F., additional, Deng, Y.-Y., additional, Boelaert, J., additional, t' Kindt, R., additional, Glorieux, G., additional, Schepers, E., additional, Jorge, L., additional, Neirynck, N., additional, Lynen, F., additional, Sandra, P., additional, Sandra, K., additional, Vanholder, R., additional, Yamamoto, T., additional, Nameta, M., additional, Yoshida, Y., additional, Uhlen, M., additional, Shi, Y., additional, Tang, J., additional, Zhang, J., additional, An, Y., additional, Liao, Y., additional, Li, Y., additional, Tao, Y., additional, Wang, L., additional, Koibuchi, K., additional, Tanaka, K., additional, Aoki, T., additional, Miyagi, M., additional, Sakai, K., additional, Aikawa, A., additional, Martins, A. R., additional, Branco, P. Q., additional, Serra, F. M., additional, Matias, P. J., additional, Lucas, C. P., additional, Adragao, T., additional, Duarte, J., additional, Oliveira, M. M., additional, Saraiva, A. M., additional, Barata, J. D., additional, Masola, V., additional, Zaza, G., additional, Granata, S., additional, Proglio, M., additional, Pontrelli, P., additional, Abaterusso, C., additional, Schena, F., additional, Gesualdo, L., additional, Gambaro, G., additional, Lupo, A., additional, Pruijm, M., additional, Hofmann, L., additional, Stuber, M., additional, Zweiacker, C., additional, Piskunowicz, M., additional, Muller, M.-E., additional, Vogt, B., additional, Burnier, M., additional, Togashi, N., additional, Yamashita, T., additional, Mita, T., additional, Ohnuma, Y., additional, Hasegawa, T., additional, Endo, T., additional, Tsuchida, A., additional, Ando, T., additional, Yoshida, H., additional, Miura, T., additional, Bevins, A., additional, Assi, L., additional, Ritchie, J., additional, Jesky, M., additional, Stringer, S., additional, Kalra, P., additional, Hutchison, C., additional, Harding, S., additional, Cockwell, P., additional, Viccica, G., additional, Cupisti, A., additional, Chiavistelli, S., additional, Borsari, S., additional, Pardi, E., additional, Centoni, R., additional, Fumagalli, G., additional, Cetani, F., additional, Marcocci, C., additional, Scully, P., additional, O'Flaherty, D., additional, Sankaralingam, A., additional, Hampson, G., additional, Goldsmith, D. J., additional, Pallet, N., additional, Chauvet, S., additional, Beaune, P., additional, Nochy, D., additional, Thervet, E., additional, Karras, A., additional, Bertho, G., additional, Gallyamov, M. G., additional, Saginova, E. A., additional, Severova, M. M., additional, Krasnova, T. N., additional, Kopylova, A. A., additional, Cho, E., additional, Jo, S.-K., additional, Kim, M.-G., additional, Cho, W.-Y., additional, kim, H. K., additional, Trivin, C., additional, Metzger, M., additional, Boffa, J.-J., additional, Vrtovsnik, F., additional, Houiller, P., additional, Haymann, J.-P., additional, Flamant, M., additional, Stengel, B., additional, Roozbeh, J., additional, Yavari, V., additional, Pakfetrat, M., additional, Zolghadr, A. A., additional, Kim, C. S., additional, Kim, M. J., additional, Kang, Y. U., additional, Choi, J. S., additional, Bae, E. H., additional, Ma, S. K., additional, Kim, S. W., additional, Lemoine, S., additional, Guebre-Egziabher, F., additional, Dubourg, L., additional, Hadj-Aissa, A., additional, Blumberg, S., additional, Katzir, Z., additional, Biro, A., additional, Cernes, R., additional, Barnea, Z., additional, Vasquez, D., additional, Gordillo, R., additional, Aller, C., additional, Fernandez, B., additional, Jabary, N., additional, Perez, V., additional, Mendiluce, A., additional, Bustamante, J., additional, Coca, A., additional, Goek, O.-N., additional, Sekula, P., additional, Prehn, C., additional, Meisinger, C., additional, Gieger, C., additional, Suhre, K., additional, Adamski, J., additional, Kastenmuller, G., additional, Kottgen, A., additional, Kuzniewski, M., additional, Fedak, D., additional, Dumnicka, P., additional, Solnica, B., additional, Kusnierz-Cabala, B., additional, Kapusta, M., additional, Sulowicz, W., additional, Drozdz, R., additional, Zawada, A. M., additional, Rogacev, K. S., additional, Hummel, B., additional, Fliser, D., additional, Geisel, J., additional, Heine, G. H., additional, Kretschmer, A., additional, Volsek, M., additional, Krahn, T., additional, Kolkhof, P., additional, Kribben, A., additional, Bruck, H., additional, Koh, E. S., additional, Chung, S., additional, Yoon, H. E., additional, Park, C. W., additional, Chang, Y. S., additional, Shin, S. J., additional, Deagostini, M. C., additional, Vigotti, F. N., additional, Ferraresi, M., additional, Consiglio, V., additional, Scognamiglio, S., additional, Moro, I., additional, Clari, R., additional, Daidola, G., additional, Versino, E., additional, Piccoli, G. B., additional, Mammadrahim Agayev, M., additional, Mehrali Mammadova, I., additional, Qarib Ismayilova, S., additional, Anguiano, L., additional, Riera, M., additional, Pascual, J., additional, Barrios, C., additional, Valdivielso, J. M., additional, Fernandez, E., additional, Soler, M. J., additional, Tsarpali, V., additional, Liakopoulos, V., additional, Panagopoulou, E., additional, Kapoukranidou, D., additional, Spaia, S., additional, Kostopoulou, M., additional, Michalaki, A., additional, Nikitidou, O., additional, Dombros, N., additional, Zhu, F., additional, Abba, S., additional, Flores-Gama, C., additional, Williams, C., additional, Cartagena, C., additional, Carter, M., additional, Kotanko, P., additional, Levin, N. W., additional, Kolesnyk, M., additional, Stepanova, N., additional, Driyanska, V., additional, Stashevska, N., additional, Kundin, V., additional, Shifris, I., additional, Dudar, I., additional, Zaporozhets, O., additional, Keda, T., additional, Ishchenko, M., additional, Khil, M., additional, Choe, J.-Y., additional, Nam, S.-A., additional, Kim, J., additional, Cha, J.-H., additional, Gliga, M. L., additional, Irimescu, C. G., additional, Caldararu, C. D., additional, Gliga, M. G., additional, Toma, L. V., additional, Gomotarceanu, A., additional, Park, Y., additional, Jeon, J., additional, Kwon, S. K., additional, Kim, S. J., additional, Kim, S. M., additional, Kim, H.-Y., additional, Montero, N., additional, Marquez, E., additional, Berrada, A., additional, Arias, C., additional, Prada, J. A., additional, Orfila, M. A., additional, Mojal, S., additional, Vilaplana, C., additional, Attini, R., additional, Parisi, S., additional, Fassio, F., additional, Ghiotto, S., additional, Biolcati, M., additional, Todros, T., additional, Jin, K., additional, Vaziri, N. D., additional, Tramonti, G., additional, Romiti, N., additional, Chieli, E., additional, Maksudova, A. N., additional, Khusnutdinova, L. A., additional, Reque, J. E., additional, Quiroga, B., additional, Lopez, J. M., additional, Verdallez, U. G., additional, Garcia de Vinuesa, M., additional, Goicoechea, M., additional, Nayara, P. G., additional, Arroyo, D. R., additional, Luno, J., additional, Tanaka, H., additional, Abbas, S. R., additional, Thijssen, S., additional, Berthoux, F. C., additional, Azzouz, L., additional, Afiani, A., additional, Ziane, A., additional, Mariat, C., additional, Fournier, H., additional, Kusztal, M., additional, Dzierzek, P., additional, Witkowski, G., additional, Nurzynski, M., additional, Golebiowski, T., additional, Weyde, W., additional, Klinger, M., additional, Altiparmak, M. R., additional, Seyahi, N., additional, Trabulus, S., additional, Bolayirli, M., additional, Andican, Z. G., additional, Suleymanlar, G., additional, Serdengecti, K., additional, Niculae, A., additional, Checherita, I.-A., additional, Neagoe, D.-N., additional, Ciocalteu, A., additional, Seiler, S., additional, Pickering, J. W., additional, Emrich, I., additional, Heine, G., additional, Bargnoux, A.-S., additional, Obiols, J., additional, Kuster, N., additional, Fessler, P., additional, Badiou, S., additional, Dupuy, A.-M., additional, Ribstein, J., additional, Cristol, J.-P., additional, Yanagisawa, N., additional, Ando, M., additional, Ajisawa, A., additional, Tsuchiya, K., additional, Nitta, K., additional, Bouquegneau, A., additional, Cavalier, E., additional, Krzesinski, J.-M., additional, Delanaye, P., additional, Tominaga, N., additional, Shibagaki, Y., additional, Kida, K., additional, Miyake, F., additional, Kimura, K., additional, Ayvazyan, A., additional, Rameev, V., additional, Kozlovskaya, L., additional, Simonyan, A., additional, Scholze, A., additional, Marckmann, P., additional, Tepel, M., additional, Rasmussen, L. M., additional, Hara, M., additional, Kanai, H., additional, Harada, K., additional, Tamura, Y., additional, Kawai, Y., additional, Al-Jebouri, M. M., additional, Madash, S. A., additional, Leonidovna Berezinets, O., additional, and Nicolaevich Rossolovskiy, A., additional
- Published
- 2013
- Full Text
- View/download PDF
32. Intracellular eukaryotic pathogens in brown macroalgae in the Eastern Mediterranean, including LSU rRNA data for the oomycete Eurychasma dicksonii
- Author
-
Strittmatter, M, primary, Gachon, CMM, additional, Müller, DG, additional, Kleinteich, J, additional, Heesch, S, additional, Tsirigoti, A, additional, Katsaros, C, additional, Kostopoulou, M, additional, and Küpper, FC, additional
- Published
- 2013
- Full Text
- View/download PDF
33. Comparative study of plasma-deposited fluorocarbon coatings on different substrates
- Author
-
Farsari, E, primary, Kostopoulou, M, additional, Amanatides, E, additional, Mataras, D, additional, and Rapakoulias, D E, additional
- Published
- 2011
- Full Text
- View/download PDF
34. Quelles politiques face aux chocs énergétiques. France, Italie, Japon, RFA: quatre modes de résorption des déséquilibres
- Author
-
Hourcade, Jean Charles, Kostopoulou, M, Laboratoire d'Informatique pour la Mécanique et les Sciences de l'Ingénieur (LIMSI), Université Paris Saclay (COmUE)-Centre National de la Recherche Scientifique (CNRS)-Sorbonne Université - UFR d'Ingénierie (UFR 919), and Sorbonne Université (SU)-Sorbonne Université (SU)-Université Paris-Saclay-Université Paris-Sud - Paris 11 (UP11)
- Subjects
[SDE]Environmental Sciences - Abstract
International audience; Confrontés aux chocs énergétiques, la France, l'Italie, le Japon et l'Allemagne ont chacun adopté une politique différente : d'une part en se dotant plus ou moins d'une capacité d'auto-approvisionnement (ainsi la France avec son parc électronucléaire et l'Allemagne avec le charbon par opposition à l'Italie et au Japon) ; d'autre part en abaissant dans des proportions fort diverses le contenu énergétique du PIB (découplage énergie/croissance) et plus spécifiquement de l'industrie. Plus fondamentalement, les auteurs montrent que la France a traité le choc pétrolier frontalement (priorité à l'offre nationale, effort d'économie d'énergie), tandis que l'Allemagne a adopté une stratégie de contournement (accumulation d'excédents commerciaux contre-balançant la facture énergétique) et que l'Italie et le Japon ont adopté une stratégie de mouvement (indirectement par les restructurations industrielles, directement en jouant sur le taux de change). Les auteurs étudient les effets de ces différentes options mais surtout ils analysent - et là, d'une certaine manière, les chocs énergétiques ne sont qu'un prétexte - comment peuvent être expliquées ces différentes options ou, plus précisément, quels sont les critères qui ont présidé aux décisions. Leur conclusion est claire : "le futur est moins déterminé par des contraintes technico-économiques que par le jeu des acteurs et leur capacité à s'entendre sur des conventions communément acceptées pour résoudre une controverse et légitimer un projet". Mieux encore, disent-ils, "toute société réagit en fonction des codes qu'elle a appris pour recevoir un message (...) et ces coûts d'information constituent typiquement un investissement irréversible..."
- Published
- 1994
35. Evaluation of spatial interpolators in the framework of a geographical information system: a case study using oceanographic data
- Author
-
Kitsiou, D., primary, Nitis, T., additional, Kostopoulou, M. N., additional, Maravelakis, N., additional, and Maneas, G., additional
- Published
- 2007
- Full Text
- View/download PDF
36. Evaluation of spatial interpolators in the framework of a geographical information system: a case study using oceanographic data.
- Author
-
Kitsiou, D., Nitis, T., Kostopoulou, M. N., Maravelakis, N., and Maneas, G.
- Published
- 2007
- Full Text
- View/download PDF
37. Chemotherapy with Methotrexate, Carboplatin, Mitoxantrone (Novantrone) and Vincristine (Oncovin) in Transitional-Cell Urothelial Cancer
- Author
-
Pectasides, D., primary, Mylonakis, A., additional, Antoniou, F., additional, Kostopoulou, M., additional, Triantaphyllis, D., additional, Papadopoulou, M., additional, Varthalitis, J., additional, Dimitriadis, M., additional, and Athanassiou, A., additional
- Published
- 1998
- Full Text
- View/download PDF
38. Paclitaxel in Cisplatin or Carboplatin-Pretreated Ovarian Cancer
- Author
-
Pectasides, D., primary, Papadopoulou, M., additional, Varthalitis, J., additional, Mylonakis, A., additional, Kostopoulou, M., additional, Dimitriadis, M., additional, and Athanassiou, A., additional
- Published
- 1998
- Full Text
- View/download PDF
39. An Outpatient Phase II Study of Subcutaneous Interleukin-2 and Interferon-Alpha-2b in Combination with Intravenous Vinblastine in Metastatic Renal Cell Cancer
- Author
-
Pectasides, D., primary, Varthalitis, J., additional, Kostopoulou, M., additional, Mylonakis, A., additional, Triantaphyllis, D., additional, Papadopoulou, M., additional, Dimitriadis, M., additional, and Athanassiou, A., additional
- Published
- 1997
- Full Text
- View/download PDF
40. CEA, CA 19-9, and CA-50 in Monitoring Gastric Carcinoma
- Author
-
Pectasides, D., primary, Mylonakis, A., additional, Kostopoulou, M., additional, Papadopoulou, M., additional, Triantafillis, D., additional, Varthalitis, J., additional, Dimitriades, M., additional, and Athanassiou, A., additional
- Published
- 1997
- Full Text
- View/download PDF
41. An Outpatient Phase II Study of Subcutaneous Interleukin-2 and Interferon-Alpha-2b in Combination with Intravenous Vinblastine in Metastatic Renal Cell Cancer.
- Author
-
Pectasides, D., Varthalitis, J., Kostopoulou, M., Mylonakis, A., Triantaphyllis, D., Papadopoulou, M., Dimitriadis, M., and Athanassiou, A.
- Subjects
CANCER patients ,LYMPHATICS ,IMMUNOMODULATORS ,LEUCOCYTOSIS ,RENAL cell carcinoma ,RENAL cancer ,CANCER research - Abstract
A prospective phase II trial was carried out to define the activity of a low-dose subcutaneous regimen of interleukin-2 (IL-2) and interferon α-2b (IFN-α) in combination with intravenous administration of vinblastine (VLB) in patients with metastatic renal cell cancer (RCC). Thirty-one patients with advanced RCC who had received no prior biochemotherapy were treated with IL-2 4.5 MU × 2/24 h thrice weekly for 2 weeks, IFN-α 3 MU/24 h thrice weekly (alternating days) for 2 consecutive weeks and VLB 4 mg/m[sup 2] every 3 weeks. Patients were to have a 1-week rest period after each 2 weeks of therapy with cytokines. Treatment was repeated every 3 weeks. Maximum duration of treatment was 1 year. Treatment was administered on an outpatient basis. There were 4 complete (12.9%) and 8 partial responses (25.8%), with an overall response rate of 38.7%. The median duration of response was 6.5 months. Responses were seen in lung, lymph nodes, bones, liver and other tumor metastases. Toxicity was mild to moderate, consisting of fever, anorexia, malaise and nausea-vomiting in >80% of patients. Hypotension and transient alopecia occurred in >20% of patients. Liver enzyme elevation was frequently observed. Treatment-induced eosinophilia occurred in the majority of patients, while in 52% of patients granulocytopenia grade II and grade III did not require dose modification of drugs. Transient inflammation and local induration at the injection sites was observed in the majority of patients. None of the patients experienced major VLB-related toxicity and no toxic deaths occurred. This three-drug combination immunochemotherapy may be a promising regimen with modest toxicity in advanced RCC. [ABSTRACT FROM AUTHOR]
- Published
- 1998
- Full Text
- View/download PDF
42. Application of different analytical methods for determination of volatile chlorination by-products in drinking water
- Author
-
Nikolaou, A. D., Lekkas, T. D., Golfinopoulos, S. K., and Kostopoulou, M. N.
- Published
- 2002
- Full Text
- View/download PDF
43. Determination of PAHs in marine sediments: Analytical methods and environmental concerns
- Author
-
Nikolaou, A., Kostopoulou, M., Lofrano, G., and Sureyya Meric
44. TOXIC EFFECTS OF AZINPHOS METHYL AND AZINPHOS ETHYL ON GROWTH AND CHLOROPHYLL PIGMENTS PRODUCTION OF MARINE UNICELLULAR MICROALGAE TETRASELMIS SUECICA
- Author
-
Petsas, A. S., Vagi, M. C., Maria Pavlaki, Smaragdaki, N. M., Kostopoulou, M. N., Lekkas, T. D., and Lekkas, Td
45. Average seasonal soil erosion and sediment deposition in the Aliakmon and Axios river catchments using the RUSLE model
- Author
-
Kitsiou, D., primary, Pataki, Z., additional, Patera, A., additional, Kontopoulos, C., additional, Karantanellis, E., additional, Nitis, T., additional, Kostopoulou, M., additional, Grammalidis, N., additional, Tzepkenlis, A., additional, and Charalampopoulou, B., additional
- Full Text
- View/download PDF
46. Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations.
- Author
-
Kostopoulou M, Mukhtyar CB, Bertsias G, Boumpas DT, and Fanouriakis A
- Subjects
- Humans, Practice Guidelines as Topic, COVID-19, SARS-CoV-2, Cyclosporine therapeutic use, Glucocorticoids therapeutic use, Lupus Erythematosus, Systemic drug therapy, Immunosuppressive Agents therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use
- Abstract
Objectives: To analyse the new evidence (2018-2022) for the management of systemic lupus erythematosus (SLE) to inform the 2023 update of the European League Against Rheumatism (EULAR) recommendations., Methods: Systematic literature reviews were performed in the Medline and the Cochrane Library databases capturing publications from 1 January 2018 through 31 December 2022, according to the EULAR standardised operating procedures. The research questions focused on five different domains, namely the benefit/harm of SLE treatments, the benefits from the attainment of remission/low disease activity, the risk/benefit from treatment tapering/withdrawal, the management of SLE with antiphospholipid syndrome and the safety of immunisations against varicella zoster virus and SARS-CoV2 infection. A Population, Intervention, Comparison and Outcome framework was used to develop search strings for each research topic., Results: We identified 439 relevant articles, the majority being observational studies of low or moderate quality. High-quality randomised controlled trials (RCTs) documented the efficacy of the type 1 interferon receptor inhibitor, anifrolumab, in non-renal SLE, and belimumab and voclosporin, a novel calcineurin inhibitor, in lupus nephritis (LN), when compared with standard of care. For the treatment of specific organ manifestations outside LN, a lack of high-quality data was documented. Multiple observational studies confirmed the beneficial effects of attaining clinical remission or low disease activity, reducing the risk for multiple adverse outcomes. Two randomised trials with some concerns regarding risk of bias found higher rates of relapse in patients who discontinued glucocorticoids (GC) or immunosuppressants in SLE and LN, respectively, yet observational cohort studies suggest that treatment withdrawal might be feasible in a subset of patients., Conclusion: Anifrolumab and belimumab achieve better disease control than standard of care in extrarenal SLE, while combination therapies with belimumab and voclosporin attained higher response rates in high-quality RCTs in LN. Remission and low disease activity are associated with favourable long-term outcomes. In patients achieving these targets, GC and immunosuppressive therapy may gradually be tapered. Cite Now., Competing Interests: Competing interests: AF reports honoraria and/or consulting fees from Lilly, Boehringer, Novartis, AbbVie, AstraZeneca, GSK, MSD, Pfizer, UCB, Amgen, Aenorasis, support for attending meetings from UCB. MK reports honoraria and/or consulting fees from GSK, participation in advisory boards from GSK, AstraZeneca, Amgen. GB reports grants from GSK, AstraZeneca, Pfizer, honoraria and/or consulting fees from Lilly, Aenorasis, Novartis, AstraZeneca, GSK, SOBI, Pfizer, participation in advisory boards from Novartis. DTB reports unrestricted investigational grants from GSK, honoraria and/or consulting fees from GSK, AstraZeneca, Pfizer. CBM declares no conflict of interest., (© European Alliance of Associations for Rheumatology, EULAR 2024. Re-use permitted under CC BY-NC-ND. No commercial re-use. No derivatives. See rights and permissions. Published by BMJ on behalf of EULAR.)
- Published
- 2024
- Full Text
- View/download PDF
47. Response to: Correspondence on 'EULAR recommendations for the management of systemic lupus erythematosus: 2023 update' by Fanouriakis et al .
- Author
-
Fanouriakis A, Kostopoulou M, Bertsias G, and Boumpas DT
- Subjects
- Humans, Lupus Erythematosus, Systemic drug therapy, Lupus Erythematosus, Systemic therapy, Practice Guidelines as Topic
- Abstract
Competing Interests: Competing interests: None declared.
- Published
- 2024
- Full Text
- View/download PDF
48. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.
- Author
-
Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, Boletis J, Bruce IN, Cervera R, Doria A, Dörner T, Furie RA, Gladman DD, Houssiau FA, Inês LS, Jayne D, Kouloumas M, Kovács L, Mok CC, Morand EF, Moroni G, Mosca M, Mucke J, Mukhtyar CB, Nagy G, Navarra S, Parodis I, Pego-Reigosa JM, Petri M, Pons-Estel BA, Schneider M, Smolen JS, Svenungsson E, Tanaka Y, Tektonidou MG, Teng YO, Tincani A, Vital EM, van Vollenhoven RF, Wincup C, Bertsias G, and Boumpas DT
- Subjects
- Humans, Tacrolimus therapeutic use, Rituximab therapeutic use, Methotrexate therapeutic use, Immunosuppressive Agents therapeutic use, Cyclophosphamide therapeutic use, Hydroxychloroquine therapeutic use, Glucocorticoids therapeutic use, Enzyme Inhibitors therapeutic use, Azathioprine therapeutic use, Lupus Erythematosus, Systemic complications
- Abstract
Objectives: To update the EULAR recommendations for the management of systemic lupus erythematosus (SLE) based on emerging new evidence., Methods: An international Task Force formed the questions for the systematic literature reviews (January 2018-December 2022), followed by formulation and finalisation of the statements after a series of meetings. A predefined voting process was applied to each overarching principle and recommendation. Levels of evidence and strengths of recommendation were assigned, and participants finally provided their level of agreement with each item., Results: The Task Force agreed on 5 overarching principles and 13 recommendations, concerning the use of hydroxychloroquine (HCQ), glucocorticoids (GC), immunosuppressive drugs (ISDs) (including methotrexate, mycophenolate, azathioprine, cyclophosphamide (CYC)), calcineurin inhibitors (CNIs, cyclosporine, tacrolimus, voclosporin) and biologics (belimumab, anifrolumab, rituximab). Advice is also provided on treatment strategies and targets of therapy, assessment of response, combination and sequential therapies, and tapering of therapy. HCQ is recommended for all patients with lupus at a target dose 5 mg/kg real body weight/day, considering the individual's risk for flares and retinal toxicity. GC are used as 'bridging therapy' during periods of disease activity; for maintenance treatment, they should be minimised to equal or less than 5 mg/day (prednisone equivalent) and, when possible, withdrawn. Prompt initiation of ISDs (methotrexate, azathioprine, mycophenolate) and/or biological agents (anifrolumab, belimumab) should be considered to control the disease and facilitate GC tapering/discontinuation. CYC and rituximab should be considered in organ-threatening and refractory disease, respectively. For active lupus nephritis, GC, mycophenolate or low-dose intravenous CYC are recommended as anchor drugs, and add-on therapy with belimumab or CNIs (voclosporin or tacrolimus) should be considered. Updated specific recommendations are also provided for cutaneous, neuropsychiatric and haematological disease, SLE-associated antiphospholipid syndrome, kidney protection, as well as preventative measures for infections, osteoporosis, cardiovascular disease., Conclusion: The updated recommendations provide consensus guidance on the management of SLE, combining evidence and expert opinion., Competing Interests: Competing interests: AF reports honoraria and/or consulting fees from Lilly, Boehringer, Novartis, Abbvie, Astra Zeneca, GSK, MSD, Pfizer, UCB, Amgen, Aenorasis, support for attending meetings from UCB. MK reports honoraria and/or consulting fees from GSK, participation in advisory boards from GSK, Astra Zeneca, Amgen. JA reports honoraria and/or consulting fees from Novartis, Astra Zeneca, support for attending meetings from Novartis, Astra-Zeneca, participation in advisory boards from Roche, Astra-Zeneca (all paid to Lupus Europe). MA reports honoraria and/or consulting fees from AbbVie, Astra Zeneca, GSK, Otsuka, Roche, support for attending meetings from Pfizer. LA reports grants from GSK, honoraria and/or consulting fees from Alexion, Alpine, Amgen, Astra Zeneca, AbbVie, Biogen, BMS, Boehringer-Ingelheim, Chugai, GSK, Grifols, Idorsia, Janssen, Kezar, Lilly, Medac, Novartis, Ono pharmaceuticals, Pfizer, Roche, UCB, support for attending meetings from Novartis, Astra-Zeneca. INB reports grants from GSK, Janssen, honoraria and/or consulting fees from Astra Zeneca, GSK, Eli Lilly, UCB, MSD, participation in advisory boards from Aurinia, Astra Zeneca, ILTOO. RC reports honoraria, consulting fees and/or participation in advisory boards from AstraZeneca, Celgene, GSK, Janssen, Lilly, Pfizer, UCB, Rubió, Werfen. AD reports honoraria and consulting fees from Otsuka, Astra Zeneca, GSK, Lilly. TD reports consulting fees from Roche, Novartis, GSK, Astra Zeneca, participation in advisory boards from GNE, Roche, Novartis. DDG reports grants from Abbvie, Amgen, BMS, Eli Lilly, Janssen, Novartis, Pfizer, UCB, consulting fees from Abbvie, Amgen, Astra Zeneca, BMS, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, UCB. FAH reports grants from GSK, Roche. DJ reports grants from GSK, Roche, CSL Vifor, honoraria and consulting fees from Astra Zeneca, Chemocentryx, GSK, Novartis, Takeda, CSL Vifor, participation in advisory boards from Chinook, GSK, stocks in Aurinia. LK reports honoraria fees from Janssen, Takeda, support for attending meetings from Abbvie, Astra Zeneca, CSL Behring, participation in advisory boards from Swixx Pharma, Roche, Astra Zeneca. CCM reports honoraria fees from GSK, support for attending meetings from Novartis. EFM reports grants from AbbVie, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Eli Lilly and Company, EMD Serono, Genentech, GlaxoSmithKline, Janssen, and UCB, honoraria and/or consulting fees from AbbVie, Astra Zeneca, Biogen, Bristol Myers Squibb, Eli Lilly and Company, EMD Serono, Galapagos, Genentech, Gilead, GlaxoSmithKline, IGM, Janssen, Novartis, Servier, Wolf, Zenas, support for attending meetings from Astra Zeneca, Roche. GM reports honoraria fees from GSK, Roche, Otsuka, participation in advisory boards from GSK, Otsuka. MM reports honoraria and/or consulting fees from Astra Zeneca, Eli Lilly, GSK, UCB, Janssen, participation in advisory boards from Idorsia. JM reports grants from GSK, honoraria and/or consulting fees from GSK, Astra Zeneca, Otsuka, BMS, participation in advisory boards from GSK, Astra Zeneca, BMS. GN reports honoraria and/or consulting fees from Sobi, GSK, Miltenyi Biotech, Swixx Biopharma, AbbVie, Lilly, Richter, Amgen, Roche, Kedrion, support for attending meetings from Roche, AbbVie, Sobi, Biotest. SVN reports honoraria and/or consulting fees from Astra Zeneca, Boehringer Ingelheim, Idorsia, Astellas, Novartis, GSK, Roche, support for attending meetings from Pfizer, participation in advisory boards from Biogen. IP reports grants from Aurinia, BMS, GSK, Otsuka, Roche, honoraria and/or consulting fees from Astra Zeneca, GSK, Janssen, Novartis, Otsuka, Roche, participation in advisory boards from Astra Zeneca, GSK, Novartis, Otsuka, medical writing from Astra Zeneca, GSK. JMPR reports grants from GSK, Pfizer, honoraria fees from GSK, Astra Zeneca, Lilly, support for attending meetings from GSK, Astra Zeneca, participation in advisory boards from GSK, Otsuka, Gebro, Astra Zeneca, Boehringer-Ingelheim, MSD. BAPE reports grants from Janssen, support for attending meetings from Astra Zeneca, participation in advisory boards from Astra Zeneca, GSK. MS reports grants from GSK, Astra Zeneca, honoraria and/or consulting fees from Astra Zeneca, GSK, Otsuka, UCB, participation in advisory boards from GSK. JSS reports grants from AbbVie, Astra Zeneca, Lilly, Galapagos, royalties or licenses from Elsevier, honoraria and/or consulting fees from AbbVie, Galapagos/Gilead, Novartis, BMS, Samsung, Sanofi, Chugai, R-Pharma, Lilly, MSD, Janssen, participation in advisory boards from Astra Zeneca. ES reports stocks in Astra Zeneca. YKOT reports grants from Mitsubishi-Tanabe, Eisai, Chugai, Taisho, consulting fees from Lilly, Astra Zeneca, AbbVie, Gilead, Chugai, Boehringer-Ingelheim, GSK, Eisai, Taisho, BMS, Pfizer, Taiho. MGT reports grants from Genesis, GSK, MSD, UCB, consulting fees from GSK, Lilly and UCB. CW reports grants from Versus Arthritis, British Society for Rheumatology, Lupus UK, honoraria fees from UCB, support for attending meetings from AbbVie. AT reports honoraria fees from UCB, GSK, participation in advisory boards from UCB, Galapagos. GB reports grants from GSK, Astra Zeneca, Pfizer, honoraria and/or consulting fees from Lilly, Aenorasis, Novartis, AstraZeneca, GSK, SOBI, Pfizer, participation in advisory boards from Novartis. DTB reports unrestricted investigational grants from GSK, honoraria and/or consulting fees from GSK, Astra-Zeneca, Pfizer. The remaining authors declare no conflict of interest., (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
49. Preventing infections in immunocompromised patients with kidney diseases: vaccines and antimicrobial prophylaxis.
- Author
-
Windpessl M, Kostopoulou M, Conway R, Berke I, Bruchfeld A, Soler MJ, Sester M, and Kronbichler A
- Subjects
- Aged, Humans, Anti-Infective Agents, COVID-19 complications, COVID-19 prevention & control, COVID-19 Vaccines, Immunosuppressive Agents therapeutic use, Vaccines, Immunocompromised Host, Kidney Diseases complications
- Abstract
The coronavirus disease 2019 (COVID-19) pandemic revealed that our understanding of infectious complications and strategies to mitigate severe infections in patients with glomerular diseases is limited. Beyond COVID-19, there are several infections that specifically impact care of patients receiving immunosuppressive measures. This review will provide an overview of six different infectious complications frequently encountered in patients with glomerular diseases, and will focus on recent achievements in terms of vaccine developments and understanding of the use of specific antimicrobial prophylaxis. These include influenza virus, Streptococcus pneumoniae, reactivation of a chronic or past infection with hepatitis B virus in cases receiving B-cell depletion, reactivation of cytomegalovirus, and cases of Pneumocystis jirovecii pneumonia in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Varicella zoster virus infections are particularly frequent in patients with systemic lupus erythematosus and an inactivated vaccine is available to use as an alternative to the attenuated vaccine in patients receiving immunosuppressants. As with COVID-19 vaccines, vaccine responses are generally impaired in older patients, and after recent administration of B-cell depleting agents, and high doses of mycophenolate mofetil and other immunosuppressants. Strategies to curb infectious complications are manifold and will be outlined in this review., (© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.)
- Published
- 2023
- Full Text
- View/download PDF
50. Annals of the Rheumatic Diseases collection on lupus nephritis (2019-2022): novel insights and advances in therapy.
- Author
-
Kostopoulou M, Fanouriakis A, Bertsias G, and Boumpas DT
- Subjects
- Humans, Lupus Nephritis drug therapy, Lupus Nephritis pathology, Lupus Erythematosus, Systemic drug therapy, Rheumatic Diseases therapy
- Abstract
No single organ has received as much attention in systemic lupus erythematosus (SLE) as the kidneys. During the period 2019-2022, the Annals of the Rheumatic Diseases published several original papers, brief reports and letters that further elucidate the pathogenesis and advance the management of LN. A selection of representative original papers is highlighted in this review., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.